Rani Therapeutics Inc. (RANI) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Rani Therapeutics Inc.

    NASDAQ: RANI · Real-Time Price · USD
    0.51
    0.01 (0.99%)
    At close: Oct 06, 2025, 3:59 PM
    0.51
    0.30%
    After-hours: Oct 06, 2025, 05:04 PM EDT

    Rani Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 1.03M n/a n/a 2.72M
    Cost of Revenue
    		 n/a 822K 1.31M n/a
    Gross Profit
    		 1.03M -822K -1.31M 2.72M
    Operating Income
    		 -53.31M -66.1M -63.45M -51.6M
    Interest Income
    		 1.76M 3.3M 1.25M 89K
    Pretax Income
    		 -30.02M -67.88M -63.27M -53.05M
    Net Income
    		 -30.02M -33.97M -63.34M -8.33M
    Selling & General & Admin
    		 23.95M 26.48M 26.84M 27.83M
    Research & Development
    		 26.68M 39.62M 36.61M 26.48M
    Other Expenses
    		 3.71M -822K -1.31M n/a
    Operating Expenses
    		 54.34M 65.28M 62.14M 54.32M
    Interest Expense
    		 5.03M 5.08M 1.07M 466K
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 54.34M 66.1M 63.45M 54.32M
    Income Tax Expense
    		 26.57M n/a 70K 41K
    Shares Outstanding (Basic)
    		 28.48M 25.5M 23.82M 19.71M
    Shares Outstanding (Diluted)
    		 28.48M 25.5M 23.82M 19.71M
    EPS (Basic)
    		 -1.05 -1.33 -1.28 -0.42
    EPS (Diluted)
    		 -1.05 -1.33 -1.28 -0.42
    EBITDA
    		 -50.52M -65.28M -60.89M -52.08M
    EBIT
    		 -51.55M -66.1M -62.2M -52.58M
    Depreciation & Amortization
    		 1.03M 822K 1.31M 497K

    Add to Watchlist